Literature DB >> 16879443

The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study.

Michael J Barry1, Michael A Delorenzo, Elizabeth S Walker-Corkery, F Lee Lucas, David C Wennberg.   

Abstract

OBJECTIVE: To investigate the effect of efforts in the early detection of prostate cancer using prostate-specific antigen (PSA) testing in the USA, by estimating the regional prevalence of androgen deprivation therapy (ADT) among older men in 1993-2000, and correlating the prevalence with early detection and aggressive treatment rates in 1987-91, as some authors predicted that ADT, a treatment traditionally reserved for advanced prostate cancer, would become less common over time as a result of such efforts. PATIENTS AND METHODS: A sample of 5% of men who were Medicare beneficiaries was used in this prospective population-based cohort study. The main outcome measures were the overall prevalence of ADT (medical and surgical) in the cohort from 1993 to 2000, and correlations between rates of prostate procedures in the 306 USA hospital referral regions in 1987-91 and prevalence of ADT in those regions from 1993 to 2000.
RESULTS: The prevalence of ADT among these men in the USA increased steadily from 1.8% in 1993 to 2.9% in 2000 (P < 0.001). Regions with higher rates of prostate biopsy in 1987-91 had a higher prevalence of ADT in 1993, 1995 and 1997 (P < 0.05). Regions with higher rates of transurethral prostatectomy in 1987-91 had a higher prevalence of ADT in 1993-2000 (P < 0.01). Regions with higher rates of radical prostatectomy in 1987-91 had higher rates of ADT in 1993-99 (P < 0.05).
CONCLUSIONS: Widespread early detection and aggressive treatment for prostate cancer in the USA has been associated with more, not less, ADT among older men over time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16879443      PMCID: PMC2121185          DOI: 10.1111/j.1464-410X.2006.06416.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  32 in total

1.  Comparison of trends in prostate-cancer mortality in England and Wales and the USA.

Authors:  S E Oliver; D Gunnell; J L Donovan
Journal:  Lancet       Date:  2000-05-20       Impact factor: 79.321

2.  Should routine screening for prostate-specific antigen be recommended?

Authors:  Siam Oottamasathien; E David Crawford
Journal:  Arch Intern Med       Date:  2003-03-24

Review 3.  The case for prostate cancer screening.

Authors:  G L Andriole
Journal:  Semin Urol       Date:  1993-05

Review 4.  Hormonal therapy in the management of prostate cancer: from Huggins to the present.

Authors:  M B Garnick
Journal:  Urology       Date:  1997-03       Impact factor: 2.649

5.  Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group.

Authors: 
Journal:  Br J Urol       Date:  1997-02

6.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

Review 7.  The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.

Authors:  D P Lubeck; G D Grossfeld; P R Carroll
Journal:  Urology       Date:  2001-08       Impact factor: 2.649

8.  Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.

Authors:  A L Potosky; K Knopf; L X Clegg; P C Albertsen; J L Stanford; A S Hamilton; F D Gilliland; J W Eley; R A Stephenson; R M Hoffman
Journal:  J Clin Oncol       Date:  2001-09-01       Impact factor: 44.544

9.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

10.  Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?

Authors:  Brenda E Sirovich; Lisa M Schwartz; Steven Woloshin
Journal:  JAMA       Date:  2003-03-19       Impact factor: 56.272

View more
  33 in total

Review 1.  Cognitive changes associated with ADT: a review of the literature.

Authors:  Rhoda J Jamadar; Mary J Winters; Pauline M Maki
Journal:  Asian J Androl       Date:  2012-02-20       Impact factor: 3.285

2.  Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.

Authors:  R B Egerdie; F Saad; M R Smith; T L J Tammela; J Heracek; P Sieber; C Ke; B Leder; R Dansey; C Goessl
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-09       Impact factor: 5.554

3.  Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

4.  Correlates of trabecular and cortical volumetric BMD in men of African ancestry.

Authors:  Yahtyng Sheu; Jane A Cauley; Clareann H Bunker; Victor W Wheeler; Alan L Patrick; Christopher L Gordon; Candace M Kammerer; Joseph M Zmuda
Journal:  J Bone Miner Res       Date:  2009-12       Impact factor: 6.741

5.  Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.

Authors:  Arnold L Potosky; Reina Haque; Andrea E Cassidy-Bushrow; Marianne Ulcickas Yood; Miao Jiang; Huei-Ting Tsai; George Luta; Nancy L Keating; Matthew R Smith; Stephen K Van Den Eeden
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

6.  Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer.

Authors:  Philip J Saylor; Matthew R Smith; A James O'Malley; Nancy L Keating
Journal:  Eur Urol       Date:  2013-02-12       Impact factor: 20.096

Review 7.  Skeletal complications of ADT: disease burden and treatment options.

Authors:  Jacques Planas Morin; Juan Morote Robles
Journal:  Asian J Androl       Date:  2012-08-20       Impact factor: 3.285

Review 8.  Metabolic complications of androgen deprivation therapy for prostate cancer.

Authors:  Philip J Saylor; Matthew R Smith
Journal:  J Urol       Date:  2009-03-14       Impact factor: 7.450

9.  Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

Review 10.  Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.

Authors:  Philip J Saylor; Nancy L Keating; Matthew R Smith
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.